Cite
MLA Citation
R Gillis et al.. “529POsimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study.” Annals of oncology, vol. 30, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100098039459.0x000032